Jerónimo Rafael Rodríguez‐Cid

7.3k total citations · 2 hit papers
31 papers, 1.1k citations indexed

About

Jerónimo Rafael Rodríguez‐Cid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jerónimo Rafael Rodríguez‐Cid has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Jerónimo Rafael Rodríguez‐Cid's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jerónimo Rafael Rodríguez‐Cid is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jerónimo Rafael Rodríguez‐Cid collaborates with scholars based in Mexico, United States and Japan. Jerónimo Rafael Rodríguez‐Cid's co-authors include Ali Tafreshi, Luis Paz‐Ares, Ying Cheng, Julien Mazières, Balázs Halmos, David Vicente, Andrew Robinson, Bilal Piperdi, Dariusz M. Kowalski and Bárbara Hermes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Jerónimo Rafael Rodríguez‐Cid

26 papers receiving 1.1k citations

Hit Papers

A Randomized, Placebo-Con... 2020 2026 2022 2024 2020 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
    2020 409 citations Luis Paz‐Ares, David Vicente et al. Journal of Thoracic Oncology profile →
  2. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
    2023 233 citations Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerónimo Rafael Rodríguez‐Cid Mexico 9 970 746 130 86 83 31 1.1k
Tania Ochi Lohmann Switzerland 4 1.1k 1.1× 836 1.1× 193 1.5× 89 1.0× 34 0.4× 5 1.2k
Marco Angelo Burgio Italy 15 676 0.7× 513 0.7× 138 1.1× 152 1.8× 60 0.7× 44 883
Santiago Ponce Aix Spain 15 620 0.6× 406 0.5× 150 1.2× 165 1.9× 80 1.0× 92 828
Tina C. Young United States 10 917 0.9× 565 0.8× 269 2.1× 139 1.6× 44 0.5× 18 1.1k
Iveta Kudaba Latvia 14 635 0.7× 490 0.7× 75 0.6× 61 0.7× 46 0.6× 24 750
J.M. Sánchez-Torres Spain 13 614 0.6× 428 0.6× 99 0.8× 150 1.7× 39 0.5× 21 772
Jun Sugisaka Japan 8 602 0.6× 287 0.4× 109 0.8× 82 1.0× 51 0.6× 20 680
Jinpeng Shi China 13 566 0.6× 446 0.6× 141 1.1× 261 3.0× 62 0.7× 27 840
Andy Karabajakian France 9 537 0.6× 246 0.3× 138 1.1× 103 1.2× 33 0.4× 19 684
Jose M. Pacheco United States 16 591 0.6× 485 0.7× 52 0.4× 196 2.3× 97 1.2× 39 800

Countries citing papers authored by Jerónimo Rafael Rodríguez‐Cid

Since Specialization
Citations

This map shows the geographic impact of Jerónimo Rafael Rodríguez‐Cid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerónimo Rafael Rodríguez‐Cid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerónimo Rafael Rodríguez‐Cid more than expected).

Fields of papers citing papers by Jerónimo Rafael Rodríguez‐Cid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerónimo Rafael Rodríguez‐Cid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerónimo Rafael Rodríguez‐Cid. The network helps show where Jerónimo Rafael Rodríguez‐Cid may publish in the future.

Co-authorship network of co-authors of Jerónimo Rafael Rodríguez‐Cid

This figure shows the co-authorship network connecting the top 25 collaborators of Jerónimo Rafael Rodríguez‐Cid. A scholar is included among the top collaborators of Jerónimo Rafael Rodríguez‐Cid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerónimo Rafael Rodríguez‐Cid. Jerónimo Rafael Rodríguez‐Cid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez-Lara, Vianey, et al.. (2025). Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile. Frontiers in Immunology. 16. 1602579–1602579. 1 indexed citations
2.
Heymach, John V., David Harpole, Janis M. Taube, et al.. (2024). OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial. Journal of Thoracic Oncology. 19(10). S38–S39. 5 indexed citations
3.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2024). Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico. PharmacoEconomics - Open. 8(6). 869–885.
4.
Novello, Silvia, Dariusz M. Kowalski, Alexander Luft, et al.. (2023). Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology. 41(11). 1999–2006. 233 indexed citations breakdown →
5.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2022). Survival prognostic factors in unresectable/advanced primary thoracic sarcomas. Journal of Thoracic Disease. 14(9). 3376–3385. 1 indexed citations
6.
Robinson, Andrew, David Vicente, Ali Tafreshi, et al.. (2021). 97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. Journal of Thoracic Oncology. 16(4). S748–S749. 15 indexed citations
7.
Whaley, Juan José Juárez‐Vignon, et al.. (2021). Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature. Case Reports in Oncology. 14(3). 1799–1805. 2 indexed citations
8.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2021). Myoepithelial Carcinoma Arising in a Plasmacytoid Myoepithelioma of the Parotid Gland Synchronized with Melanoma: A Case Report and Review of the Literature. Case Reports in Oncology. 14(1). 173–183. 2 indexed citations
9.
Powell, Steven, Delvys Rodríguez‐Abreu, Corey J. Langer, et al.. (2021). Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology. 16(11). 1883–1892. 130 indexed citations
10.
Baas, Paul, Arnaud Scherpereel, Anna K. Nowak, et al.. (2020). ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Thoracic Oncology. 15(10). e42–e42. 37 indexed citations
11.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2020). Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma. Thoracic Cancer. 11(11). 3243–3251. 1 indexed citations
12.
Paz‐Ares, Luis, David Vicente, Ali Tafreshi, et al.. (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology. 15(10). 1657–1669. 409 indexed citations breakdown →
13.
Barrón, Feliciano, Andrés F. Cardona, Saúl Campos-Gómez, et al.. (2020). Brigatinib in ALK -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). Future Oncology. 17(2). 169–181. 7 indexed citations
14.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2019). Clinical-epidemiological and molecular description of lung cancer in a national reference center. 78(4). 356–362.
15.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2019). Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 38(3). 271–280. 57 indexed citations
16.
17.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2019). Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma. Journal of Thoracic Disease. 11(4). 1456–1464. 6 indexed citations
18.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2018). Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Annals of Oncology. 29. viii748–viii749. 2 indexed citations
19.
Rodríguez‐Cid, Jerónimo Rafael, et al.. (2014). Uso de ipilimumab en pacientes con melanoma metastásico. Experiencia en el Hospital Médica Sur. Gaceta Mexicana de Oncología. 13(3). 157–161. 1 indexed citations
20.
Morales-Espinosa, Daniela, David Cantú de León, Dan Green, et al.. (2013). Characterization of DNA methylation of the promoters CTCF and BORIS (CTCFL) in breast and ovarian cancer.. Journal of Clinical Oncology. 31(15_suppl). e22151–e22151. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tania Ochi Lohmann Breakdown of academic impact, for papers by Marco Angelo Burgio Breakdown of academic impact, for papers by Santiago Ponce Aix Breakdown of academic impact, for papers by Tina C. Young Breakdown of academic impact, for papers by Iveta Kudaba Breakdown of academic impact, for papers by J.M. Sánchez-Torres Breakdown of academic impact, for papers by Jun Sugisaka Breakdown of academic impact, for papers by Jinpeng Shi Breakdown of academic impact, for papers by Andy Karabajakian Breakdown of academic impact, for papers by Jose M. Pacheco
Rankless by CCL
2026